Category Archives: Non-U.S. Practice

Do You Really Want to File for Pharma Patent Protection in Canada, India or Ecuador?

IPO Letter Reports Weaknesses in IP Protection Around the World In a 27 page letter dated February 8, 2018 and sent to Sue Chang at the Office of the U.S. Trade Representative, the Executive Director of IPO, Mark Lauroesch, extensively … Continue reading

Posted in Govt Policy/PTO Policy, Int'l Practice and Policy, Non-U.S. Practice | Tagged , , | 1 Comment

Patenting “Natural Products” Down-Under Post-Myriad

Although the Australian High Court held that claims to naturally occurring DNA (e.g., BRCA1 nucleic acid) were not patent eligible because they were not a “manner of manufacture,” since the encoded information therein was not “made” by human action, in … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , | 1 Comment

A Hidden Danger Under The EPC – The “Extension Trap”

Provided to us by Dr. Stefan Danner of DHS Patentanwalts GmbH, find below the current issue of the biotech IP newsletter dealing with recent EPO case law on Article 123(2)(3) EPC. Extension Trap

Posted in Non-U.S. Practice | Tagged , , , | Leave a comment

Biotech IP Newsletters

Find below biotech IP newsletters recently provided by Dr. Stefan Danner. SPCs For Combination Products – Opinion Of The Advocate General EPO Ruling On The Patentability Of Medical Treatments By Therapy  

Posted in Non-U.S. Practice | Tagged , , , , | Leave a comment